Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes? (UD)
Myelodysplastic Syndrome
About this trial
This is an interventional treatment trial for Myelodysplastic Syndrome focused on measuring MDS, myeloid clonal disorder
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years of age
- Diagnosis of MDS (Myelodysplastic syndrome ) without leukemia (IPSS-R classified or physician indicated either low-risk or intermediate-1)
- Stable disease (as assessed by the patient's physician using MDS Stability Assessment Algorithm)
- Blood group A, B, or AB
- Requiring 2 RBC units at least every 6 weeks or less
- Receiving transfusions in an outpatient setting
Exclusion Criteria:
- Unable to provide informed consent
- Blood group O
- Clinical requirement for special products because of reactions (e.g. washed or volume-reduced)
Sites / Locations
- Juravinski Hospital and Cancer CentreRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
ABO non-identical transfusion
ABO identical transfusion
All study patients will participate in the study for two consecutive transfusion episodes (a transfusion episode is defined as a clinic visit where 2 RBC units are transfused) and will receive an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. Randomization will dictate the order of the transfusion. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
All study patients will participate in the study for two consecutive transfusion episodes (a transfusion episode is defined as a clinic visit where 2 RBC units are transfused) and will receive an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. Randomization will dictate the order of the transfusion. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.